SELLAS Life Sciences Group Inc buy Heureka
Start price
27.02.20
/
50%
€2.39
Target price
09.03.20
€3.00
Performance (%)
-23.10%
End price
09.03.20
€1.84
Summary
This prediction ended on 09.03.20 with a price of €1.84. The prediction for SELLAS Life Sciences Group Inc disappointed with a performance of -23.10%. Heureka has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | -1.848% | -1.848% | 601.909% | 580.912% |
| iShares Core DAX® | 1.001% | 4.831% | 8.149% | 62.596% |
| iShares Nasdaq 100 | 2.702% | -1.720% | 26.924% | 88.135% |
| iShares Nikkei 225® | 3.519% | -3.506% | 48.064% | 78.113% |
| iShares S&P 500 | 1.766% | 1.273% | 23.577% | 70.466% |